WO2003032988A1 - Composition pharmaceutique - Google Patents
Composition pharmaceutique Download PDFInfo
- Publication number
- WO2003032988A1 WO2003032988A1 PCT/JP2002/010707 JP0210707W WO03032988A1 WO 2003032988 A1 WO2003032988 A1 WO 2003032988A1 JP 0210707 W JP0210707 W JP 0210707W WO 03032988 A1 WO03032988 A1 WO 03032988A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen
- pharmaceutical composition
- halogeno
- general formula
- compound represented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne une composition pharmaceutique permettant d'administrer un composé représenté par la formule générale (I) ou analogue ainsi qu'un composé représenté par la formule générale (II), soit simultanément, soit séparément à un intervalle de temps. Dans ces formules, X est un groupe cyclique benzimidazole ; Y1 représente oxygène ou soufre, Z représente un groupe thiazolidinedione ou analogue ; R représente hydrogène, un groupe alkyle en C1-6 ou analogue ; m est un nombre entier compris entre 1 et 5 ; Ra représente bromo ou iodo ; Rb représente hydrogène, halogéno ou analogue ; Rc représente NRKOR1 [où RK représente hydrogène ou analogue ; et R1 représente un groupe cycloalkyle en C3-10 ou analogue] ; et Rd, Re, et Rf représentent indépendamment les uns des autres hydrogène, halogéno ou analogue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001319631 | 2001-10-17 | ||
JP2001-319631 | 2001-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003032988A1 true WO2003032988A1 (fr) | 2003-04-24 |
Family
ID=19137153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010707 WO2003032988A1 (fr) | 2001-10-17 | 2002-10-16 | Composition pharmaceutique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003032988A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010070379A1 (fr) * | 2008-12-17 | 2010-06-24 | Centre National De La Recherche Scientifique | Traitement combiné d'agoniste rxr-ppargamma/d'inhibiteur de facteur de croissance, servant à l'induction de l'apoptose et au traitement du cancer |
AU2007213028B2 (en) * | 2006-02-09 | 2010-10-28 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025598A2 (fr) * | 1996-12-11 | 1998-06-18 | Dana-Farber Cancer Institute | Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales |
WO1998037881A1 (fr) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek |
EP1022272A1 (fr) * | 1997-10-08 | 2000-07-26 | Sankyo Company Limited | Composes heterocycliques condenses substitues |
WO2000061581A1 (fr) * | 1999-04-07 | 2000-10-19 | Sankyo Company, Limited | Derives amine |
JP2000351779A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | アミン誘導体化合物 |
-
2002
- 2002-10-16 WO PCT/JP2002/010707 patent/WO2003032988A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025598A2 (fr) * | 1996-12-11 | 1998-06-18 | Dana-Farber Cancer Institute | Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales |
WO1998037881A1 (fr) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek |
EP1022272A1 (fr) * | 1997-10-08 | 2000-07-26 | Sankyo Company Limited | Composes heterocycliques condenses substitues |
WO2000061581A1 (fr) * | 1999-04-07 | 2000-10-19 | Sankyo Company, Limited | Derives amine |
JP2000351779A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | アミン誘導体化合物 |
Non-Patent Citations (1)
Title |
---|
CAMP HEIDI S. ET AL.: "Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 16, 1997, pages 10811 - 10816, XP002961077 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007213028B2 (en) * | 2006-02-09 | 2010-10-28 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
AU2007213028C1 (en) * | 2006-02-09 | 2011-05-19 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
US8263631B2 (en) | 2006-02-09 | 2012-09-11 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer |
WO2010070379A1 (fr) * | 2008-12-17 | 2010-06-24 | Centre National De La Recherche Scientifique | Traitement combiné d'agoniste rxr-ppargamma/d'inhibiteur de facteur de croissance, servant à l'induction de l'apoptose et au traitement du cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2477839A1 (fr) | Azote contenant des composes heterocycliques et medicaments ainsi constitues | |
WO2003033493A1 (fr) | Activateur du recepteur $g(d) active par le proliferateur de peroxisome | |
EP1669352A4 (fr) | Derive thiazoline et utilisation | |
DE60218048D1 (de) | Thiophenverbindungen als arzneimittel | |
EP0894797A4 (fr) | Nouveaux derives d'amide et intermediaires utilises pour leur synthese | |
WO2002100812A1 (fr) | Dérivé de l'acide carboxylique et son sel | |
EP1510516A4 (fr) | Compose de pyrazole et composition medicinale le contenant | |
EP1780209A4 (fr) | Compose de type ester d'oxime et initiateur de photopolymerisation contenant un compose de ce type | |
HUP0302153A2 (hu) | Kemokin receptor aktívitás modulátoraiként hatásos piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
EP1396493A4 (fr) | Composes heterocycliques | |
EP1582521A4 (fr) | Compose de furane condense | |
HK1071565A1 (en) | 6,7-Dihydro-5H-pyrazolo Ä1,2-AÜ pyrazol-1-ones which control inflammatory cytokines | |
EP1284266A4 (fr) | Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation | |
WO2003059907A1 (fr) | Composes heterocycliques azotes : procede de preparation et d'utilisation | |
WO2004099145A3 (fr) | Derives cycliques a substitution phenyle | |
WO2001012202A3 (fr) | Utilisation d'agents chimiques chelatants comme agents de neutralisation du blocage neuromusculaire provoque par des medicaments | |
CA2226886A1 (fr) | Derives d'aminolactames n-(4-substitue-benzyl)-2 | |
WO2003031414A1 (fr) | Nouveau compose heterocyclique et agent anti-inflammatoire | |
WO2003032988A1 (fr) | Composition pharmaceutique | |
EP1550651A4 (fr) | Derive glycerol | |
HK1043784A1 (en) | Processes for preparing pesticidal intermediates. | |
EP1310490A4 (fr) | Antagoniste de gpr14 | |
WO2003018591A1 (fr) | Derives d'acide b pseudo-lariques, preparation et compositions pharmaceutiques correspondantes | |
EP1797879A4 (fr) | Nouveau médicament anti-microbien | |
WO2002060878A1 (fr) | Derives de benzimidazolidinone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |